- Home
- QNCX
as 07-04-2025 10:36am EST
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 47.7M | IPO Year: | 2019 |
| Target Price: | $8.00 | AVG Volume (30 days): | 353.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.51 - $2.45 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Quince Therapeutics Inc. News
QNCX Breaking Stock News: Dive into QNCX Ticker-Specific Updates for Smart Investing
Business Wire
11 days ago
Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference
Business Wire
18 days ago
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
Simply Wall St.
21 days ago
June 2025's Promising Penny Stocks For Savvy Investors
MT Newswires
24 days ago
Quince Therapeutics Prices $22 Million Private Placement of Shares, Warrants
Business Wire
24 days ago
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
MT Newswires
a month ago
Quince Therapeutics Says Enrollment for Phase 3 Clinical Trial in Ataxia-Telangiectasia Exceeds 75%
Business Wire
a month ago
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Business Wire
2 months ago
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
Compare QNCX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QNCX Quince Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.